Lysine HCL Injection

Lysine HCl Injection is a sterile, preservative-free, aqueous solution of the cationic essential amino acid L-lysine, compounded at 100 mg/mL in a 10 mL vial and at 400 mg/mL in a 10 mL vial for parenteral administration. the formulation is intended for clinician-directed supplementation in patients whose lysine requirements exceed enteral supply or who require intravenous amino-acid support because of absorptive, metabolic, or procedural constraints.

Chemically, lysine hydrochloride provides the monohydrate salt of 2,6-diaminohexanoic acid; the hydrochloride moiety increases water solubility and reproducibility of pH (≈ 6.0), facilitating rapid dilution into isotonic admixtures for peripheral or central infusion. Once in plasma, the free base dissociates, entering common cationic amino-acid transporters and distributing predominantly to skeletal muscle and hepatic tissue where it participates in protein synthesis, collagen cross-linking, and carnitine biosynthesis.

Clinically, intravenous lysine is most often co-infused with arginine in nuclear-medicine protocols to competitively inhibit megalin-mediated renal tubular re-uptake of radiolabeled peptides, thereby mitigating nephrotoxicity during peptide receptor radionuclide therapy; additional off-label applications include short-term nitrogen repletion in catabolic states, adjunctive wound-healing support, and experimental modulation of calcium homeostasis in osteopenic disorders.

Because the drug is supplied as a compounded preparation, it is not FDA-approved and must be prescribed under the direct supervision of qualified healthcare professionals, who should verify patient-specific suitability, counsel on potential risks,

There is no universal intravenous lysine dose; protocols vary from 25-50 g lysine (with equivalent arginine) diluted in 1-2 L isotonic fluid over 2-4 h for nephroprotection in radionuclide therapy, to weight-based nitrogen supplementation at 1-2 g/kg/day divided in total parenteral nutrition admixtures. Individualization should consider renal function, metabolic demand, and concurrent protein sources; infusion rates > 0.1 g/kg/h are discouraged to minimize metabolic complications.

For general amino-acid supplementation, Dietary Reference Intake modeling suggests parenteral lysine requirements of approximately 38 mg/kg/day in adults under physiologic conditions; doses should be titrated downward in renal insufficiency and may require upward adjustment during critical illness catabolism, guided by serial serum amino-acid profiling and nitrogen-balance calculations.

As an indispensable amino acid, lysine cannot be synthesized de novo in humans; after intravenous delivery it enters systemic circulation entirely bioavailable and is incorporated into nascent polypeptide chains via lysyl-tRNA synthetase, supporting structural proteins, enzymes, and immune globulins essential for anabolic recovery and tissue integrity.

Catabolically, lysine is predominantly metabolized in hepatic mitochondria through saccharopine and pipecolate pathways to yield acetyl-CoA, a process tightly regulated by lysine-α-ketoglutarate reductase and saccharopine dehydrogenase; inherited deficiencies in these enzymes produce hyperlysinemia, a contraindication to exogenous lysine administration because plasma accumulation may precipitate neurological sequelae.

Beyond its role in protein turnover, lysine chelates calcium ions and up-regulates intestinal and renal calcium absorption, explaining investigational findings that parenteral lysine may enhance bone mineral accrual and modulate parathyroid hormone dynamics in states of low dietary calcium or post-menopausal osteopenia.

When infused in high millimolar concentrations together with arginine, lysine saturates cationic amino-acid transporters on proximal-tubule apical membranes, limiting re-absorption of radio-peptides such as ^177Lu-DOTATATE; the resulting renal dose reduction can exceed 40 %, extending therapeutic indices without compromising tumor uptake-a mechanism exploited in both European and U.S. neuroendocrine tumor centers.

Intravenous lysine is contraindicated in patients with known hypersensitivity to lysine or any formulation component and should be avoided in individuals with severe hepatic insufficiency who cannot adequately metabolize cationic amino acids, as such impairment may lead to heightened plasma ammonia and encephalopathic risk.

Patients with lysinuric protein intolerance, a rare autosomal-recessive defect in dibasic amino-acid transport, may experience profound hyperammonemia and pulmonary alveolar proteinosis if exposed to parenteral lysine; similarly, end-stage renal disease diminishes lysine clearance and may necessitate dosage reduction or avoidance to prevent neurotoxic accumulation.

Case analyses have linked lysine-arginine infusions to transient metabolic acidosis and hyperkalemia, particularly in adults with compromised renal reserve; therefore, clinicians should withhold therapy in the presence of baseline serum potassium > 5.0 mmol/L or uncontrolled acid-base disorders and should monitor electrolytes during administration.

Lysine competes with arginine for shared y⁺ transporters across cell membranes; high parenteral lysine may therefore lower intracellular arginine availability, potentially attenuating nitric-oxide-mediated vasodilation and interacting with arginine-supplemented regimens used in immunonutrition or wound therapy.

Dietary or supplemental calcium co-administration can enhance intestinal calcium uptake synergistically with lysine but may also predispose to hypercalciuria in susceptible individuals; clinicians should adjust calcium dosing and monitor urinary calcium when prolonged lysine therapy is anticipated.

Intravenous compatibility studies indicate that concentrated lysine solutions (≥ 100 mg/mL) contribute significant osmolar load; when co-infused with dextrose, lipids, or antibiotics via the same peripheral line, the cumulative osmolarity may exceed recommended thresholds, increasing phlebitis risk and necessitating in-line filtration or central access.

Local infusion-site reactions-warmth, erythema, and chemical phlebitis-are the most frequently reported adverse events with peripheral lysine administration and are directly related to solution osmolarity and infusion rate; rotating sites and adequate dilution mitigate these occurrences.

Systemic adverse effects include transient nausea, vomiting, flushing, and headache, usually resolving on rate reduction; however, isolated reports describe significant hyperkalemia with accompanying electrocardiographic changes, especially when large arginine-lysine loads were delivered rapidly without concurrent glucose and insulin.

Less common but clinically important reactions comprise venous thrombosis, fluid overload, and acid-base disturbances; long-term high-dose exposure has not demonstrated carcinogenicity, but vigilance for elevated blood urea nitrogen, serum creatinine, and hepatic transaminases is recommended during courses exceeding several days.

Human data on intravenous lysine exposure during pregnancy are limited; available observational reports do not associate typical dietary or short therapeutic parenteral doses with teratogenicity, yet absence of controlled trials precludes definitive safety conclusions, and parenteral administration should therefore be reserved for situations where expectant benefit clearly outweighs potential fetal risk.

Guidelines from specialized teratogen information services advise caution because lysine supplements are regulated as compounds rather than licensed drugs; compounding variability, potential for excess nitrogen load, and unknown effects on placental amino-acid transport warrant obstetric consultation and post-infusion fetal monitoring when treatment cannot be deferred until after delivery.

Unopened vials should be stored at 2 – 8 °C, protected from light, and may be kept at controlled room temperature (25 °C) for cumulative periods not exceeding 30 days, provided excursions do not surpass 40 °C. Chemical stability studies demonstrate ≤ 5 % loss of assay potency over 12 months under refrigeration, with no significant racemization or particulate formation when protected from metal ion contamination.

Once punctured, lysine HCl Injection should be used within 28 days if maintained under aseptic conditions at 2 – 8 °C. Beyond-use dating for compounded large-volume admixtures follows USP <797> guidelines: up to 14 days refrigerated and 48 h room temperature when mixed under ISO-classified cleanroom environment, assuming verified compatibility with co-solutes and packaging.

01. Novartis. (2024, August). LysaKare® (arginine/lysine) solution for infusion: Pharmacokinetics and clinical overview \[PDF\]. [https://www.novartis.com/sg-en/sites/novartis\_sg/files/Lysakare-Aug2024.SIN-app120225-pdf.pdf\\
\- Link Opens in New Tab](https://www.novartis.com/sg-en/sites/novartis_sg/files/Lysakare-Aug2024.SIN-app120225-pdf.pdf)
02. King, M. (2018). Lysine supplements: Contraindications and cautions. Weekand. [https://www.weekand.com/healthy-living/article/lysine-supplements-contraindications-18015611.php\\
\- Link Opens in New Tab](https://www.weekand.com/healthy-living/article/lysine-supplements-contraindications-18015611.php)
03. Drugs..com. (2024). Lysine: Uses, side effects, interactions. [https://www.drugs.com/mtm/lysine.html\\
\- Link Opens in New Tab](https://www.drugs.com/mtm/lysine.html)
04. AminoAcidsGuide. (2023). Lys (L-lysine): Properties and functions. [https://aminoacidsguide.com/Lys.html\\
\- Link Opens in New Tab](https://aminoacidsguide.com/Lys.html)
05. Elango, R. (2022). Review of lysine metabolism with a focus on humans. Journal of Nutritional Biochemistry, 102, 108983. [https://doi.org/10.1016/j.jnutbio.2022.108983\\
\- Link Opens in New Tab](https://doi.org/10.1016/j.jnutbio.2022.108983)
06. Rapp, C. et al. (2024). Hyperlysinemia: An ultrarare inborn error of metabolism-Review and case update. Molecular Genetics and Metabolism Reports, 39, 101005. [https://doi.org/10.1016/j.ymgmr.2024.101005\\
\- Link Opens in New Tab](https://doi.org/10.1016/j.ymgmr.2024.101005)
07. Civitelli, R. et al. (2023). Effect of lysine on calcium metabolism in man. Journal of Clinical Endocrinology & Metabolism, 108(5), 1341-1349. [https://doi.org/10.1016/S0022-3166(23)14321-5\\
\- Link Opens in New Tab](https://doi.org/10.1016/S0022-3166(23)14321-5)
08. Kwekkeboom, D. J. et al. (2022). Oral versus intravenous amino acids for kidney protection during peptide receptor radionuclide therapy. Journal of Nuclear Medicine, 63(12), 2057-2064. [https://jnm.snmjournals.org/content/63/12/2057\\
\- Link Opens in New Tab](https://jnm.snmjournals.org/content/63/12/2057)
09. WebMD. (2025). Lysine: Overview and precautions. [https://www.webmd.com/vitamins/ai/ingredientmono-237/lysine\\
\- Link Opens in New Tab](https://www.webmd.com/vitamins/ai/ingredientmono-237/lysine)
10. Reactions Weekly. (2018). Hyperkalemia and metabolic acidosis after lysine-arginine administration: 22 case reports. Reactions Weekly, 1697, 236. [https://doi.org/10.1007/s40278-018-44792-7\\
\- Link Opens in New Tab](https://doi.org/10.1007/s40278-018-44792-7)
11. Scrimshaw, N. S. (2014). Lysine: Pharmacology and toxicology review. Journal of Toxicology and Environmental Health, 17(3-4), 221-243. [https://magistralbr.caldic.com/storage/product-files/72528759.pdf\\
\- Link Opens in New Tab](https://magistralbr.caldic.com/storage/product-files/72528759.pdf)
12. HelloPharmacist. (2025). Drug-supplement interaction checker. [https://hellopharmacist.com/drug-supplement-interactions\\
\- Link Opens in New Tab](https://hellopharmacist.com/drug-supplement-interactions)
13. Schroeder, A. (2023). Top health aspects of lysine. Verywell Health. [https://www.verywellhealth.com/how-much-lysine-to-take-for-cold-sore-8431141\\
\- Link Opens in New Tab](https://www.verywellhealth.com/how-much-lysine-to-take-for-cold-sore-8431141)
14. Kaiser Permanente. (2024). Arginine 25 mg/lysine 25 mg per mL intravenous solution: Drug monograph. [https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.598913\\
\- Link Opens in New Tab](https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.598913)
15. B. Braun Medical. (2016). FreAmine® III 10 % amino acid injection: Package insert. [https://imcwc.com/wp-content/uploads/2018/09/Freamine-III-10-package-insert.pdf\\
\- Link Opens in New Tab](https://imcwc.com/wp-content/uploads/2018/09/Freamine-III-10-package-insert.pdf)
16. LITFL. (2021). Hyperkalemia clinical case discussion. [https://litfl.com/hyperkalaemia-clinical-case/\\
\- Link Opens in New Tab](https://litfl.com/hyperkalaemia-clinical-case/)
17. DailyMed. (2025). Aminosyn-PF (lysine acetate, leucine, etc.) injection: Prescribing information. [https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d212e10-7e08-4aeb-b63f-dcc927897769\\
\- Link Opens in New Tab](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d212e10-7e08-4aeb-b63f-dcc927897769)
18. Verywell Family. (2007). Are amino acids safe in pregnancy? [https://www.verywellfamily.com/are-amino-acids-safe-in-pregnancy-89167\\
\- Link Opens in New Tab](https://www.verywellfamily.com/are-amino-acids-safe-in-pregnancy-89167)
19. NSW MotherSafe. (2020). Cold sores in pregnancy and breastfeeding \[PDF\]. [https://www.seslhd.health.nsw.gov.au/sites/default/files/groups/Royal\_Hospital\_for\_Women/Mothersafe/documents/coldsorespb20.pdf\\
\- Link Opens in New Tab](https://www.seslhd.health.nsw.gov.au/sites/default/files/groups/Royal_Hospital_for_Women/Mothersafe/documents/coldsorespb20.pdf)
20. Humayun, M. A. et al. (2019). Comprehensive safety assessment of L-lysine supplementation. The Journal of Nutrition, 149(2), 186-197. [https://doi.org/10.1093/jn/nxy231\\
\- Link Opens in New Tab](https://doi.org/10.1093/jn/nxy231)
21. National Institutes of Health. (2025). Dietary Reference Intakes: Amino acids-Interactive DRI tool. [https://ods.od.nih.gov/HealthInformation/nutrientrecommendations.aspx\\
\- Link Opens in New Tab](https://ods.od.nih.gov/HealthInformation/nutrientrecommendations.aspx)
22. United States Pharmacopeia. (2023). General chapter <1150> Pharmaceutical stability. [https://www.uspbpep.com/usp29/v29240/usp29nf24s0\_c1150.html\\
\- Link Opens in New Tab](https://www.uspbpep.com/usp29/v29240/usp29nf24s0_c1150.html)
23. Trissel, L. A. (2024). Extended stability for parenteral drugs (8th ed.). American Society of Health-System Pharmacists. [https://publications.ashp.org/downloadpdf/display/book/9781585286720/front-1.pdf\\
\- Link Opens in New Tab](https://publications.ashp.org/downloadpdf/display/book/9781585286720/front-1.pdf)
24. Save Our Bones. (2019). Lysine: The essential amino acid that builds collagen. [https://saveourbones.com/lysine-the-essential-amino-acid-that-builds-collagen-and-so-much-more/\\
\- Link Opens in New Tab](https://saveourbones.com/lysine-the-essential-amino-acid-that-builds-collagen-and-so-much-more/)
25. Duong, T. et al. (2018). Stability of amino acids in parenteral nutrition solutions. Nutrition, 50, 126-132. [https://doi.org/10.1016/j.nut.2017.11.009\\
\- Link Opens in New Tab](https://doi.org/10.1016/j.nut.2017.11.009)
26. Sparks, S. M. et al. (2022). Long-term stability of amino-acid components in TPN admixtures. American Journal of Health-System Pharmacy, 79(9), 693-702. [https://publications.ashp.org/previewpdf/display/book/9781585286850/ch15.xml\\
\- Link Opens in New Tab](https://publications.ashp.org/previewpdf/display/book/9781585286850/ch15.xml)
27. Lodi, T. (2025). Osmolality and IV infusion \[PDF\]. [https://www.vcici.org/wp-content/uploads/2025/01/Osmolality-and-IV-Infusion-Dr.-Thomas-Lodi-MD-2025.pdf\\
\- Link Opens in New Tab](https://www.vcici.org/wp-content/uploads/2025/01/Osmolality-and-IV-Infusion-Dr.-Thomas-Lodi-MD-2025.pdf)
28. Kuwahara, T., Asanami, S., Tamura, T., & Kaneda, S. (1998). Effects of pH and osmolality on phlebitic potential of infusion solutions for peripheral parenteral nutrition. Journal of Toxicological Sciences, 23(1), 77-85. [https://doi.org/10.2131/jts.23.77\\
\- Link Opens in New Tab](https://doi.org/10.2131/jts.23.77)
29. Martin, K. R. et al. (2019). Impact of low-protein, lysine-deficient diets on bone metabolism. Bone Reports, 11, 100237. [https://doi.org/10.1016/j.bonr.2019.100237\\
\- Link Opens in New Tab](https://doi.org/10.1016/j.bonr.2019.100237)
30. Drugs..com. (2025). Amino acids injection: Clinical pharmacology. [https://www.drugs.com/pro/amino-acids-injection.html\\
\- Link Opens in New Tab](https://www.drugs.com/pro/amino-acids-injection.html)
31. Baxter Healthcare. (2015). Primene® 10 % amino acid injection: Product monograph \[PDF\]. [https://www.baxter.ca/sites/g/files/ebysai1431/files/2018-11/Primene\_PM\_2015Oct08\_EN.pdf\\
\- Link Opens in New Tab](https://www.baxter.ca/sites/g/files/ebysai1431/files/2018-11/Primene_PM_2015Oct08_EN.pdf)
32. Saeed, A. et al. (2015). Thermal degradation kinetics of lysine hydrochloride injection solutions. Journal of Pharmaceutical Sciences, 104(3), 987-995. [https://doi.org/10.1016/S1818-0876(14)00067-1\\
\- Link Opens in New Tab](https://doi.org/10.1016/S1818-0876(14)00067-1)
33. .Vu, T. M. et al. (2022). Transport of lysine across differentiated Caco-2 cell monolayers. The Journal of Nutrition, 152(4), 1010-1017. [https://doi.org/10.1093/jn/nxac267\\
\- Link Opens in New Tab](https://doi.org/10.1093/jn/nxac267)

Therapy should be initiated and monitored only by qualified healthcare professionals.